SynAct Pharma (STO: SYNACT)

Last close As at 14/11/2025

SEK21.25

−0.50 (−2.30%)

Market capitalisation

SEK1,160m

SynAct Pharma is a clinical-stage biotechnology company focussed on the development of treatments to resolve, rather than inhibit, ongoing inflammatory processes in acute and chronic diseases.

Latest Insights

View More

Healthcare | Update

SynAct Pharma — Approaching a catalyst-rich period

Healthcare | Initiation

SynAct Pharma — Differentiated inflammation resolution approach

Healthcare | edison tv

SynAct Pharma – executive interview

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Jeppe Øvlesen

    CEO

  • Björn Westberg

    CFO